Summit Therapeutics Inc (SMMT)

07:30 AM

This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year - Yahoo Finance

07:30 AM

Mar 12, 2025

Summit gains as Evercore highlights potential to rival Merck’s Keytruda - MSN

Mar 12, 2025

Mar 12, 2025

Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target -March 12, 2025 at 12:08 pm EDT - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

Summit Therapeutics Shares Surge on Promising Trial Results - TipRanks

Mar 12, 2025

Mar 12, 2025

Evercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform Recommendation - Nasdaq

Mar 12, 2025

Mar 12, 2025

Summit Therapeutics initiated with an Outperform at Evercore ISI - TipRanks

Mar 12, 2025

Mar 11, 2025

12 Best Multibagger Stocks to Buy in 2025 - Insider Monkey

Mar 11, 2025

Mar 11, 2025

Stifel maintains Buy on Summit Therapeutics, $40 target By Investing.com - Investing.com Canada

Mar 11, 2025

Mar 08, 2025

Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? - Insider Monkey

Mar 08, 2025

Mar 05, 2025

New York State Common Retirement Fund Grows Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Mar 05, 2025

Mar 05, 2025

Principal Financial Group Inc. Acquires 147,003 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Mar 05, 2025

Mar 05, 2025

Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by StockNews.com - Defense World

Mar 05, 2025

Mar 04, 2025

(SMMT) Investment Analysis and Advice - Stock Traders Daily

Mar 04, 2025

Mar 04, 2025

Rhumbline Advisers Has $2.23 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Mar 04, 2025

Mar 01, 2025

Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group - MarketBeat

Mar 01, 2025

Mar 01, 2025

Equities Analysts Offer Predictions for SMMT Q1 Earnings - MarketBeat

Mar 01, 2025

Mar 01, 2025

Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 01, 2025

Mar 01, 2025

Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN

Mar 01, 2025

Feb 28, 2025

StockNews.com Downgrades Summit Therapeutics (NASDAQ:SMMT) to Sell - MarketBeat

Feb 28, 2025

Feb 28, 2025

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Feb 28, 2025

Feb 28, 2025

Summit Therapeutics Stock Surges Amid Promising Trials - TipRanks

Feb 28, 2025

Feb 28, 2025

Goldman Sachs Initiates Summit Therapeutics at Buy With $42 Price Target -February 28, 2025 at 08:12 am EST - Marketscreener.com

Feb 28, 2025

Feb 28, 2025

Summit Therapeutics's Options Frenzy: What You Need to Know - Benzinga India

Feb 28, 2025

Feb 27, 2025

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 15.6%Time to Sell? - MarketBeat

Feb 27, 2025

Feb 27, 2025

Summit Therapeutics (NASDAQ:SMMT) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat

Feb 27, 2025

Feb 27, 2025

Brokerages Set Summit Therapeutics Inc. (NASDAQ:SMMT) Price Target at $33.57 - MarketBeat

Feb 27, 2025

Feb 27, 2025

Summit Therapeutics Inc. (SMMT): Among the Stocks That Will Go to the Moon According to Analysts - MSN

Feb 27, 2025

Feb 26, 2025

Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown - MSN

Feb 26, 2025

Feb 25, 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2024 Earnings Call Transcript - MSN

Feb 25, 2025

Feb 25, 2025

Why Summit Therapeutics Inc. (SMMT) Went Down On Monday? - Insider Monkey

Feb 25, 2025

Feb 25, 2025

Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - MSN

Feb 25, 2025

Feb 25, 2025

Positive Outlook for Summit Therapeutics: Strategic Collaborations and Promising Trials Justify Buy Rating - TipRanks

Feb 25, 2025

Feb 25, 2025

Summit inks ADCs deal with Pfizer - The Pharma Letter

Feb 25, 2025

Feb 25, 2025

Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: - GuruFocus.com

Feb 25, 2025

Feb 25, 2025

Buy Rating for Summit Therapeutics Driven by Strategic Pfizer Collaboration and Promising Clinical Trial Readouts - TipRanks

Feb 25, 2025

Feb 25, 2025

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus.com

Feb 25, 2025

Feb 25, 2025

Summit Therapeutics’ Earnings Call Highlights: Collaborations and Clinical Progress - TipRanks

Feb 25, 2025

Feb 25, 2025

Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance

Feb 25, 2025

Feb 25, 2025

Summit Therapeutics: Strong Financials and Strategic Collaborations Drive Buy Rating - TipRanks

Feb 25, 2025

Feb 25, 2025

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs - Lelezard

Feb 25, 2025

Feb 24, 2025

15 Stocks That Will Go to The Moon According to Analysts - Insider Monkey

Feb 24, 2025

Feb 24, 2025

Summit Therapeutics Reports 2024 Financials and Progress - TipRanks

Feb 24, 2025

Feb 24, 2025

Summit Therapeutics Highlights Q4 Results and FDA Fast Track - TipRanks

Feb 24, 2025

Feb 24, 2025

Can This Summit-Pfizer Cancer Drug Combo Revolutionize Solid Tumor Treatment? - StockTitan

Feb 24, 2025

Feb 24, 2025

SMMTSummit Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 24, 2025

Feb 24, 2025

Earnings call transcript: Summit Therapeutics Q4 2024 sees stock drop 13.6% - Investing.com Australia

Feb 24, 2025

Feb 24, 2025

U.S. Markets Closed Mixed Monday As Sun Communities Led, Summit Therapeutics Lagged - Barron's

Feb 24, 2025

Feb 24, 2025

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program (SMMT) - Seeking Alpha

Feb 24, 2025

Feb 24, 2025

Stifel maintains Summit Therapeutics at Hold with $40 target - Investing.com

Feb 24, 2025

Feb 24, 2025

Stifel maintains Summit Therapeutics at Hold with $40 target By Investing.com - Investing.com South Africa

Feb 24, 2025

Feb 24, 2025

Summit Therapeutics falls on wider Q4 loss, deal expectations from investors - TradingView

Feb 24, 2025

Feb 24, 2025

Stifel Reiterates Hold Rating on Summit Therapeutics plc (SMMT) - StreetInsider.com

Feb 24, 2025

Feb 24, 2025

Summit Therapeutics announces clinical trial collaboration with Pfizer - MSN

Feb 24, 2025

Feb 24, 2025

Summit Therapeutics advances ivonescimab with Pfizer collaboration and expanded trials - MSN

Feb 24, 2025